Bourne, Garrett Diebold, Kendall Espinoza-Gutarra, Manuel Al-Kadhimi, Zaid Bachiashvili, Kimo Rangaraju, Sravanti Vachhani, Pankit Bhatia, Ravi Jamy, Omer
Published in
Leukemia research
In a meta-analysis of 5 trials, the addition of gemtuzumab ozogamicin (GO) to intensive induction chemotherapy led to a survival benefit in patients with core-binding factor (CBF) acute myeloid leukemia (AML). Given the heterogeneous incorporation of GO in clinical trials, the ideal dose and schedule remains unclear. We conducted a single-center re...
Castro, Giovanna A. Almeida, Jade M. Machado-Neto, João A. Almeida, Tiago A.
Published in
Frontiers in Artificial Intelligence
Introduction Acute Myeloid Leukemia (AML) is one of the most aggressive hematological neoplasms, emphasizing the critical need for early detection and strategic treatment planning. The association between prompt intervention and enhanced patient survival rates underscores the pivotal role of therapy decisions. To determine the treatment protocol, s...
ABBASIZADEH, NASTARAN
Hematopoiesis depends on complex interactions between hematopoietic stem cells (HSCs) and the bone marrow (BM) microenvironment. However, alterations in this regulated system can lead to malignant transformation and hematopoietic diseases. Acute myeloid leukemia (AML) is characterized by uncontrolled growth of leukemic blasts in the BM and is the m...
Oswald, Laura B Venditti, Adriano Cella, David Cottone, Francesco Candoni, Anna Melillo, Lorella Cairoli, Roberto Storti, Gabriella Salutari, Prassede Luppi, Mario
...
Published in
BMJ supportive & palliative care
This study compared the burden of fatigue between treatment-naïve patients with newly diagnosed acute myeloid leukaemia (AML) and the general population and investigated patient factors associated with fatigue severity. Pretreatment patient-reported fatigue was assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire...
Alhattab, Dana M Isaioglou, Ioannis Alshehri, Salwa Khan, Zainab N Susapto, Hepi H Li, Yanyan Marghani, Yara Alghuneim, Arwa A Díaz-Rúa, Rubén Abdelrahman, Sherin
...
Published in
Biomaterials research
Acute myeloid leukemia (AML) is a hematological malignancy that remains a therapeutic challenge due to the high incidence of disease relapse. To better understand resistance mechanisms and identify novel therapies, robust preclinical models mimicking the bone marrow (BM) microenvironment are needed. This study aimed to achieve an automated fabricat...
Maillet, François
Les téloméropathies, également appelées syndrome des télomères courts (STC), regroupent un ensemble de maladies liées à des mutations germinales dans les gènes du complexe télomérase et du complexe shelterin, responsables d’un raccourcissement prématuré des télomères. Le STC associe de manière variable des anomalies cutanéo-muqueuses, pulmonaires, ...
E Silva, Bianca Faville, Charline Jassin, Mégane DUBOIS, Sophie De Voeght, Adrien Baron, Frédéric Ehx, Grégory
Acute myeloid leukemia (AML) is a lethal adult leukemia with high remission rates (~75%) after chemotherapy. Thus, high-risk AML patients often undergo allogeneic hematopoietic cell transplantation (allo-HCT), the only curative treatment option currently available. Allo-HCT relies on the elimination of the blasts that survived chemotherapy by matur...
Pagliuca, Simona Gurnari, Carmelo Hercus, Colin Hergalant, Sébastien Hong, Sanghee Dhuyser, Adele D’Aveni, Maud Aarnink, Alice Rubio, Marie Thérèse Feugier, Pierre
...
Published in
Research Square
Graft-versus-leukemia (GvL) reactions are responsible for the effectiveness of allogeneic hematopoietic cell transplantation as a treatment modality for myeloid neoplasia, whereby donor T- effector cells recognize leukemia neoantigens. However, a substantial fraction of patients experience relapses because of the failure of the immunological respon...
Gallo Marin, Benjamin Ollila, Thomas A Robbins, Allison Brooks, Blake E Firoz, Elnaz F Massoud, Cathy M
Published in
American journal of hematology
Firouzi, Javad Hajifathali, Abbas Azimi, Masoumeh Parvini, Neda Ghaemi, Fatemeh Shayan Asl, Niloufar Hedayati Asl, Amir Abbas Safa, Majid Ebrahimi, Marzieh
Published in
Cell Journal (Yakhteh)
Objective: Natural killer (NK) cells are critical immune cells for acute myeloid leukemia (AML) targeting. However, little is known about the relationship between using checkpoint inhibitors and heat shock protein 70 (Hsp70) as NK cell activators to control AML. Therefore, the study aims to find the best formulation of Hsp70, human PD-1 (Programmed...
